CoLucid Pharmaceuticals (CLCD) IPO Opens Down 15%

Today's IPO for CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) opened for trading at $8.50 after pricing 5,500,000 shares of common stock at a public offering price of $10.00 per share.

Piper Jaffray & Co. and Stifel are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. is acting as lead manager and Ladenburg Thalmann is acting as co-manager for the offering.

CoLucid was founded by Pappas Ventures and is developing oral Lasmiditan for the acute treatment of migraine headache and intravenous Lasmiditan for treatment of headache pain by health care professionals.

You May Also Be Interested In

• Lyntris files for IPO, plans to list on NYSE under "LYNX"
• Open AI Adding Two Independent Board Members Ahead of IPO - WSJ
• William Blair Downgrades Pegasystems (PEGA) to Market Perform